Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0340 • ACR Convergence 2021
Urinary L-selectin Predicts Disease Activity and Histological Changes in Lupus Nephritis
Huihua Ding¹, Yiwei Shen¹, Min Dai¹, Chandra Mohan² and Nan Shen³, ¹Shanghai JiaoTong University School of Medicine, Shanghai, China (People's Republic), ²University of Houston, Houston, TX, ³Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: There remains unmet needs of non-invasive markers of disease activity, damage, prognosis, and treatment response in lupus nephritis patients. Here, we aim to validate…
Abstract Number: 0471 • ACR Convergence 2021
Therapeutic Efficacy of BT-104, an Oral LANCL2 Agonist, for the Treatment of Systemic Lupus Erythematosus
Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni, Sarah Fitch, Jyoti Chauhan and Josep Bassaganya-Riera, Landos Biopharma, Blacksburg, VA
Background/Purpose: Systemic lupus erythematosus is a complex disease in which the immune system is dysfunctional at multiple levels including impaired regulatory responses, altered self-antigen processing…
Abstract Number: 0597 • ACR Convergence 2021
Sex Differences in Multimorbidity Between Patients with Systemic Lupus Erythematosus and Comparators in a Large Nationwide US Study
Ali Duarte-Garcia¹, Herbert Heien¹, Nilay Shah¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased burden of multimorbidity. Although many comorbidities may vary by sex and men with lupus may…
Abstract Number: 0768 • ACR Convergence 2021
Poverty and Length of Stay in Children Hospitalized with Pediatric Systemic Lupus Erythematosus: An Analysis of the 2016 Kids’ Inpatient Database
William Soulsby, Erica Lawson and Matthew Pantell, University of California San Francisco, San Francisco, CA
Background/Purpose: Prior studies have demonstrated alarming health disparities in adult patients with SLE, including higher disease severity and activity among Hispanic and Black patients. Pediatric…
Abstract Number: 0865 • ACR Convergence 2021
Lupus Low Disease Activity State Attainment Provides Significant Protection Against Mortality: A Multi-National, Longitudinal Observational Study
Rangi Kandane-Rathnayake¹, Vera Golder¹, Worawit Louthrenoo², YI-HSING CHEN³, Jiacai Cho⁴, Aisha Lateef⁵, Laniyati Hamijoyo⁶, Shue-Fen Luo⁷, Yeong-Jian Wu⁸, Sandra Navarra⁹, Leonid Zamora⁹, Zhanguo Li¹⁰, Yuan An¹⁰, Sargunan Sockalingam¹¹, Yasuhiro Katsumata¹², Masayoshi Harigai¹², Yanjie Hao¹³, Zhuoli Zhang¹³, B.M.D.B. Basnayake¹⁴, Madelynn Chan¹⁵, Jun Kikuchi¹⁶, Tsutomu Takeuchi¹⁷, Shereen Oon¹⁸, Sang-Cheol Bae¹⁹, Sean O’Neill²⁰, Fiona Goldblatt²¹, Kathryn Gibson²⁰, Kristine (Pek Ling) Ng²², Annie Law²³, Nicola Tugnet²⁴, Sunil Kumar²⁵, Michael Tee²⁶, DaeYoung Yu²⁷, Chetan Karyekar²⁸, Yoshiya Tanaka²⁹, C.S. Lau³⁰, Mandana Nikpour³¹, Alberta Hoi³² and Eric Morand³³, ¹Monash University, Clayton, Australia, ²Maharaj Nakorn Chiangmai, Chiang Mai, Thailand, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴National University Health System (NUHS), Singapore, Singapore, ⁵National University Hospital, Singapore, Singapore, ⁶University of Padjadjaran, Bandung, Indonesia, ⁷Chang Gung Memorial Hospital, Taipei, Taiwan, ⁸Chang Gung Memorial Hospital, Taoyuan County, Taiwan, ⁹University of Santo Tomas Hospital, Manila, Philippines, ¹⁰People's Hospital, Peking University Health Science Center, Beijing, China (People's Republic), ¹¹University of Malaya, Kuala Lumpur, Malaysia, ¹²Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹³Peking University First Hospital, Beijing, China (People's Republic), ¹⁴Teaching (General) Hospital, Kandy, Sri Lanka, ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶Keio University, Tokyo, Japan, ¹⁷Div. Rheumatology, Keio University, Tokyo, Japan, ¹⁸Melbourne Health, Parkville, Australia, ¹⁹Hanyang University Medical Center, Seoul, Republic of Korea, ²⁰Liverpool Hospital, Sydney, Australia, ²¹Flinders Medical Centre, Adelaide, Australia, ²²North Shore Hospital, Auckland, New Zealand, ²³Singapore General Hospital, Singapore, Singapore, ²⁴Auckland District Health Board, Auckland, New Zealand, ²⁵Counties Manukau Health, Auckland, New Zealand, ²⁶University of the Philippines, Quezon City, Philippines, ²⁷Janssen Asia Pacific, Seoul, Republic of Korea, ²⁸Janssen R&D, Spring House, PA, ²⁹University of Occupational and Environmental Health, Kitakyushu, Japan, ³⁰University of Hong Kong, Hong Kong, Hong Kong, ³¹University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ³²Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, ³³School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia
Background/Purpose: Mortality in patients with systemic lupus erythematosus (SLE) is high compared to the general population. Attainment of the Lupus Low Disease Activity State (LLDAS)…
Abstract Number: 0881 • ACR Convergence 2021
Economic Evaluation of Neuropsychiatric (NP) Lupus in an International Inception Cohort Using a Multistate Model Approach
Ann Clarke¹, John Hanly², Yvan St.Pierre³, Caroline Gordon⁴, Sang-Cheol Bae⁵, Juanita Romero-Diaz⁶, Jorge Sanchez-Guerrero⁷, Sasha Bernatsky⁸, Daniel Wallace⁹, David Isenberg¹⁰, Anisur Rahman¹¹, Joan Merrill¹², Paul R Fortin¹³, Dafna Gladman¹⁴, Murray Urowitz¹⁵, Ian N. Bruce¹⁶, Michelle Petri¹⁷, Ellen Ginzler¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Susan Manzi²¹, Andreas Jnsen²², Graciela Alarcn²³, Ronald van Vollenhoven²⁴, Cynthia Aranow²⁵, Meggan Mackay²⁵, Guillermo Ruiz-Irastorza²⁶, S Sam Lim²⁷, Murat Inanc²⁸, Kenneth Kalunian²⁹, Soren Jacobsen³⁰, Christine Peschken³¹, Diane Kamen³², Anca Askanase³³ and Vernon Farewell³⁴, ¹University of Calgary, Calgary, AB, Canada, ²Dalhousie University, Halifax, NS, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁵Hanyang University Medical Center, Seoul, Republic of Korea, ⁶Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ⁷Instituto Nacional de Ciencias Médicas y Nutrición, Inmunología y Reumatología, Mexico City, Mexico, ⁸McGill University, Montréal, QC, Canada, ⁹Cedars-Sinai, Los Angeles, CA, ¹⁰Centre for Rheumatology, University College London, London, United Kingdom, ¹¹University College London, London, United Kingdom, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁵Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ¹⁶University of Manchester, Manchester, United Kingdom, ¹⁷Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸SUNY Downstate Health Sciences University, Brooklyn, NY, ¹⁹Raleigh Neurology Associates, Chapel Hill, NC, ²⁰Northwestern University, Chicago, IL, ²¹Allegheny Health Network, Wexford, PA, ²²Lund University, Lund, Sweden, ²³University of Alabama at Birmingham, Birmingham, AL, ²⁴Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ²⁷Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ²⁸Istanbul University Faculty of Medicine, Istanbul, Turkey, ²⁹UC San Diego, La Jolla, CA, ³⁰Rigshospitalet, Copenhagen, Denmark, ³¹University of Manitoba, Winnipeg, MB, Canada, ³²Medical University of South Carolina, Charleston, SC, ³³Columbia University Medical Center, New York, NY, ³⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Little is known about the economic burden of NP lupus. We estimated annual and cumulative direct and indirect costs (DC, IC) associated with NP…
Abstract Number: 0966 • ACR Convergence 2021
Integrated Single Cell RNA-Sequencing Analysis of Tissue-Localized T Cells in Cutaneous Lupus and Lupus Nephritis
Garett Dunlap¹, Allison Billi², Feiyang Ma³, Johann Gudjonsson², J. Michelle Kahlenberg⁴ and Deepak Rao⁵, ¹Harvard University, Somerville, MA, ²Department of Dermatology, University of Michigan, Ann Arbor, MI, ³University of California Los Angeles, Los Angelas, CA, ⁴University of Michigan, Ann Arbor, MI, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Cutaneous lupus erythematosus (CLE) is commonly present in patients with systemic lupus erythematosus (SLE), but can also exist as an isolated manifestation without further…
Abstract Number: 1054 • ACR Convergence 2021
Metabolomics as an Innovative Tool for Cardiac Risk Stratification in Patients with Rheumatic Diseases: Results from a Pilot Study
Sorwe Mojtahed Poor¹, Lisa Hahnefeld², Frank Behrens³, Harald Burkhardt⁴, Michaela Köhm⁵, Geisslinger Gerd⁶ and Gurke Robert⁷, ¹University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, ²pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany, Frankfurt, Germany, ³Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany, ⁴University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ⁵University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, ⁶Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ⁷pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany
Background/Purpose: Patients with rheumatic diseases (RMD) face an increased cardiovascular (CV) mortality compared to the general population. Still, risk stratification based on traditional cardiovascular risk…
Abstract Number: 1262 • ACR Convergence 2021
Fish Oil Supplementation and Pro-inflammatory and Pro-Resolving Lipid Mediators in Patients with and Without Systemic Lupus Erythematosus
May Choi¹, Nancy Cook², Emma Stevens², Natalya Gomelskaya², Gregory Kotler³, JoAnn Manson³, Jessica Lasky-Su², Raju Tatituri², Samia Mora², I-Min Lee³, Charles Serhan² and Karen Costenbader⁴, ¹Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Belmont, MA
Background/Purpose: Omega-3 fatty acid-derived “specialized pro-resolving mediators” (SPM) are low-abundance lipid mediators (LM) central to inflammation resolution. In this cross-sectional study, we investigated whether fish…
Abstract Number: 1278 • ACR Convergence 2021
Clinical Outcomes in a Cohort of Puerto Ricans with Systemic Lupus Erythematosus After SARS CoV-2 Infection
Ariana González-Meléndez¹ and Luis Vilá², ¹University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: The coronavirus disease 2019 (COVID-19) pandemic is of particular concern for people with autoimmune rheumatic diseases and for those who are immunosuppressed given the…
Abstract Number: 1294 • ACR Convergence 2021
Predictors of BILAG-based Outcomes in Patients with SLE: Analysis from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort and MASTERPLANS Consortium
Trixy David¹, Li Su², Yafeng Cheng², Caroline Gordon³, Benjamin Parker¹, David Isenberg⁴, John A Reynolds⁵ and Ian N Bruce⁶, ¹The Kellgren Centre for Rheumatology, and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ²MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom, ³Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁴Centre for Rheumatology, University College London, London, United Kingdom, ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, and Rheumatology Department, City Hospital, Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom, ⁶The Kellgren Centre for Rheumatology; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, and Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Several novel SLE therapies are in development. Precision medicine aims to improve treatment practices and real-world outcomes. Certain factors, however, will likely reflect overall…
Abstract Number: 1431 • ACR Convergence 2021
Human TLR8 Leads to Fatal Anemia Due to Ineffective Erythropoiesis in Bone Marrow Erythroblastic Islands in Murine SLE
Naomi Maria¹, Julien Papoin¹, Chirag Raparia¹, Zeguo Sun², Shani Martinez¹, Weijia Zhang², Lionel Blanc¹ and Anne Davidson¹, ¹Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ²Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: There are multiple causes of anemia in SLE including hemolysis, inflammation, renal insufficiency and, more rarely, microangiopathy, hemophagocytosis and bone marrow insufficiency. One cause…
Abstract Number: 1488 • ACR Convergence 2021
Metabolic Alterations of Systemic Lupus Erythematosus NK Cells Determine Response to Anti-CD38 and Anti-SLAMF7 Monoclonal Antibodies
Morgane Humbel, Natalia Fluder, Florence Bellanger, Alice Horisberger, Craig Fenwick, Camillo Ribi and Denis Comte, CHUV, Lausanne, Switzerland
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem inflammatory condition of unknown pathogenesis. We have previously shown that SLE Natural killer (NK) cells are decreased…
Abstract Number: 1506 • ACR Convergence 2021
SLAMF6 Compartmentalization Regulates Autoimmune T Cell Responses
Yevgeniya Gartshteyn¹, Anca Askanase² and Adam Mor³, ¹Columbia University Medical Center, Glen Rock, NJ, ²Columbia University Medical Center, New York, NY, ³CUIMC, New York, NY
Background/Purpose: T cell activation is initiated by engagement of the T cell receptor (TCR) complex and requires co-receptor signaling. SLAMF6 is a major T cell…
Abstract Number: 1718 • ACR Convergence 2021
Use of Gonadotropin Releasing Hormone Agonist for Ovarian Preservation in SLE Patients on Cyclophosphamide
Jun Chu¹, Alice Fike², Michael Davis³, Zerai Manna⁴, Komal Ejaz⁵, Yenealem Temesgen-Oyelakin⁶, Elaine Poncio⁷, Isabel Ochoa⁷, Alan Decherney⁴ and Sarfaraz Hasni⁴, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ³NIAMS, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵Sheikh Zayed Medical College, Scranton, PA, ⁶National Institutes of Health (NIH), Bethesda, MD, ⁷NIH/NIAMS, Bethesda, MD
Background/Purpose: SLE is an autoimmune disease which predominantly affects women of childbearing age (age 20-40). Most of the medications used for treating SLE can adversely…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].